• 专利标题:   Detecting analytes associated with disease or condition in subject, comprises measuring resistance of device contact with sample obtained from subject.
  • 专利号:   US2022167873-A1
  • 发明人:   EKENSEAIR A K, EMAM S, SUN N X
  • 专利权人:   UNIV NORTHEASTERN
  • 国际专利分类:   A61B005/08, A61B005/097, G01N027/04, G01N027/327
  • 专利详细信息:   US2022167873-A1 02 Jun 2022 A61B-005/097 202255 English
  • 申请详细信息:   US2022167873-A1 US453941 08 Nov 2021
  • 优先权号:   US657312P, US453941

▎ 摘  要

NOVELTY - Detecting at least one analytes associated with a disease or condition in a subject suspected to have the disease or condition, comprises measuring the resistance of a device that has been or is in contact with a sample obtained from the subject, the device comprises at least one layers of metal on a layer of silicon, and a layer of molecularly imprinted polymer that is selective for the at least one analytes associated with the disease or condition in electrical communication with the at least one layers of metal, where the at least one layers of metal are each independently selected from a layer of chromium, platinum, gold, nickel, cobalt, tungsten, rhodium, iridium, silver, tin, titanium or tantalum, or its an alloy, and the device has an inherent resistance, and a difference between the inherent resistance of the device and the resistance of the device contacted with the sample indicates at least one analytes associated with the disease or condition have been detected. USE - The method is useful: for detecting analytes associated with a disease or condition in a subject suspected to have the disease or condition, where the disease or condition is alzheimer's disease, lung cancer; and for diagnosing a disease or condition in a subject suspected to have the disease or condition, or at risk for developing the disease or condition (all claimed). ADVANTAGE - The method which as devices have been demonstrated to show sensitivity of from 20-100 parts per trillion, to be highly selective, and to be capable of differentiating between transgenic human APE4 knock-in rats with AD and healthy controls.